Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three University-based laboratories of the same area

Liver Transplantation

Volumn 15, Issue 3, 2009, Pages 300-305

  Xiol, Xavier ^a   Gines, Pere ^b   Castells, Lluis ^c   Twose, Jorge ^d   Ribalta, Alba ^d   Fuentes Arderiu, Xavier ^a   Rodriguez, Santiago ^c   Castellote, Jose ^a   Navasa, Miquel ^b   Deulofeu, Roser ^d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Pav Helios 3   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; SODIUM;

ACCURACY; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL LABORATORY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE; MODEL FOR END STAGE LIVER DISEASE SODIUM SCORE; MORTALITY; ORGAN TRANSPLANTATION; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SODIUM BLOOD LEVEL; SURVIVAL;

BILIRUBIN; CREATININE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; MODELS, BIOLOGICAL; SEVERITY OF ILLNESS INDEX; SODIUM; SPAIN; UNIVERSITIES; WAITING LISTS;

EID: 67649219724     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21688     Document Type: Article

References (23)

1. Kamath PSK, Kim R. The Model for End-Stage Liver Disease (MELD). Hepatology 2007;45:795-805.
2. Cholongitas E, Marelli L, Shusang V, Senzolo M, Rolles K, Patch D, Borroughs AK. A systematic review of the performance of the Model for End-Stage Liver Disease (MELD) in the setting of liver transplantation. Liver Transpl 2006;12: 1049-1061.
3. Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher Model for End-Stage Liver Disease (MELD) scores for patients for liver transplantation. Liver Transpl 2004;10:995-1000.
4. Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and Model for End-Stage Liver Disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007;7:1624-1628.
5. Cholongitas E, Marelli L, Kerry A, Senzolo M, Goodier DW, Nair D, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007;13: 523-529.
6. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40:802-810.
7. Biggins SW, Rodriguez HJ, Baccheti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41: 32-39.
8. Loroño M, Cárdenas A, Guevara M, Quintó L, Heras L, Navasa M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007;6:1283-1290.
9. Mathur S, Gane EJ, McCall JL, Plank LD. Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis. J Gastroenterol Hepatol 2008;23:239-243.
10. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-343.
11. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130:1652-1660.
12. Ravaioli M, Masetti M, Ridolfi L, Capelli M, Grazi GL, Venturoli N, et al. Laboratory test variability and Model-for End-Stage Liver Disease score calculation: effect on liver allocation and proposal for adjustment. Transplantation 2007;83:919-924.
13. Robert A, Chazouilleres O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?. Hepatology 1996;24:1392-1394.
14. Marlar RA. Determining the Model for End-Stage Liver Disease with better accuracy. Neutralizing the international normalized ratio pitfalls. Hepatology 2007;46:295-296.
15. Tripodi A, Chantarangkul V, Primignani M, Fabris F, Dell'Era A, Sei C, Mannucci PM. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for Model for End-Stage Liver Disease calculation. Hepatology 2007;46:520-527.
16. Bellest L, Eschwège V, Poupon R, Chazouillères O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007;46:528-534.
17. Ford L, Berg J. Delay in separating samples affects creatinine measurement using Roche kinetic Jaffe method. Ann Clin Biochem 2008;45:83-87.
18. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956;271:121-125.
19. Arroyo V, Rodes J, Gutierrez MA, Revert L. Prognostic value of hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976;21:249-256.
20. Fernandez Esparrach G, Sanchez Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
21. Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000;32:605-610.
22. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007;13: 1174-1180.
23. Neuberger J, Gimson, Davies M, Akyol M, O'Grady, Burroughs A, Hudson M, for the Liver Advisory Group of UK Blood and Transplant. Selection of patients for liver transplantation and allocation of donated livers in UK. Gut 2008;57:252-257.